Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748852 | 0.89 | PARP1 (0.33) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL15635817 | 0.89 | PARP1 (0.33) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL153211 | 0.79 | AHR (0.45) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL12078457 | 0.79 | PARP1 (0.58) | PARP1MAPTNR3C1PGRNR3C2 | |
| SCHEMBL31394015 | 0.76 | MAPT (0.36) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL6342164 | 0.76 | MAPT (0.36) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL30768351 | 0.76 | PARP1 (0.39) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL14758337 | 0.76 | MAPT (0.36) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL21893243 | 0.76 | ALOX15 (0.40) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL30079633 | 0.76 | MAPT (0.36) | PARP1MAPTNPSR1RXFP1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | PARP1 584/4885MAPT 3029/4885NPSR1 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.